Abstracts tagged "risk assessment"

Abstract Number: 0498 • ACR Convergence 2024
ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Welch¹, Yangyuna Yang¹, Joshua Baker², Katherine Wysham³, Dana Ascherman⁴, Paul Monach⁵, Gail Kerr⁶, Andreas Reimold⁷, grant Cannon⁸, Gary Kunkel⁹, William Robinson¹⁰, Michael Duryee¹, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵VA Boston Healthcare System, Boston, MA, ⁶Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁷Dallas VA Medical Center, Dallas, TX, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹⁰Stanford University, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…
Abstract Number: 1336 • ACR Convergence 2024
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³ and Masayoshi Harigai⁴, ¹Meiji Pharmaceutical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Showa University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
Abstract Number: 2125 • ACR Convergence 2024
Strengthening Fracture Risk Prediction in Rheumatoid Arthritis: Integrating a Self-report Sarcopenia Screening Tool (SARC-F) and Fracture Risk Assessment Tool (FRAX) Scores
Ana Rodriguez-Flores¹, Ana Cecilia Bardan-Inchaustegui², Mara Ponce², Galilea Rodriguez³, Anahí Carrazco Chapa⁴, Valeria Monserrat De Hoyos-Perez⁵, Gilberto J Cervantes Charles⁵, Alma Damian Peñaloza⁵, Cinthia Maribel Cortez Lopez⁵, CASSANDRA SKINNER TAYLOR⁶, Roberto Negrete Lopez⁵, Jesus Cardenas-de la Garza² and Dionicio Galarza-Delgado⁷, ¹Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Mexico, ⁴Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ⁵Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁶HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of fractures due to factors such as chronic inflammation, use of glucocorticoids, and reduced muscle mass.…
Abstract Number: 0564 • ACR Convergence 2024
The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study
Mayas Arraf¹, Devy Zisman², walid Saliba³, Nili Stein⁴ and Joy Feld⁵, ¹Technion medical school, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel medical center, Haifa, Israel, ⁴Department of Community Medicine and Epidemiology, Haifa, Israel, ⁵Carmel and Zvulun Medical Centre, Haifa, Israel
Background/Purpose: Scarce data exist regarding the incidence of venous thromboembolism events (VTE); pulmonary embolism (PE) and deep vein thrombosis (DVT), in patients with axial spondylarthritis…
Abstract Number: 1347 • ACR Convergence 2024
Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
Manon Lesturgie-Talarek¹, Fabien Picard², sabrina hamroun³, Malika Saadi², Camille Macher⁴, Aude Deloumeau³, Karim Wahbi², jacques Blacher⁴, Yannick Allanore⁵ and Jérôme Avouac⁶, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Cardiology Department - Cochin Hospital, Paris, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Cardiology Department, Hôtel Dieu Hospital, Paris, France, ⁵Université Paris Cité, Paris, France, ⁶Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular (CV) mortality, linked to systemic inflammation and the presence of associated CV risk factors.…
Abstract Number: 2235 • ACR Convergence 2024
The Updated PREVENT (Predicting Risk of CVD EVENTs) Algorithm Is Not Able to Indicate Subclinical Coronary or Carotid Atherosclerosis Better Than the Traditional Pooled Cohort Equations in Rheumatoid Arthritis
J. Alex B. Gibbons¹, Joan Bathon² and Jon Giles³, ¹Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ²Columbia University, NEW YORK, NY, ³Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with RA are at increased risk of atherosclerotic cardiovascular disease (ASCVD), yet traditional 10-year CVD risk calculators—such as the 2013 Pooled Cohort Equations…
Abstract Number: 0612 • ACR Convergence 2024
Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort
Nevin Hammam¹, Ahmed Elsaman², Esam Abualfadl³, Soha Senara⁴, Nada M. Gamal⁵, Mona H. Abd Elsamea⁵, Abdelhfeez Moshrif⁶, Samar Tharwat⁷, Osman Hammam⁸ and Tamer A Gheita⁹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt; Qena/Luxor Hospitals, Qena, Egypt, Sohag, Egypt, ⁴Rheumatology Department, Faculty of Medicine, Fayoum University,, Fayoum, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Assiut, Egypt, ⁶Al-azhar university, Assiut, Egypt, ⁷Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ⁸Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a great heterogeneity and unpredictable flare. In managing patients with SLE, the diagnosis…
Abstract Number: 1505 • ACR Convergence 2024
Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
Sara Ferrigno¹, Elizabeth Arkema², Lina Marcela Diaz-Gallo³, Iva Gunnarsson⁴, Agneta Zickert⁴ and Elisabet Svenungsson⁵, ¹Department of Systems' Medicine, University of Rome Tor Vergata, Rome, Italy, ²Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Sweden, ³Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) patients have higher cardiovascular (CV) risk compared to the general population, with a standardized CV mortality rate of 2-3 and…
Abstract Number: 2326 • ACR Convergence 2024
Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
Michael Dreyfuss¹, Dan Riesel², Guy Shalev², Benjamin Getz³, Or Ramni², Yonatan Jenudi⁴, Dimid Duchovny², Daniel Underberger⁵, Shlomit Steinberg-Koch², Douglas White⁶ and Elena Myasoedova⁷, ¹Predicta Med, Ramat Gan, Israel, ²Predicta Med Analytics Ltd., Ramat Gan, Israel, ³CTO, Ramat Gan, Israel, ⁴[email protected], Ramat Gan, Israel, ⁵Predicta Med Analytics Ltd., Bridgeport, CT, ⁶Gundersen Health System, Onalaska, WI, ⁷Mayo Clinic, Rochester, MN
Background/Purpose: Delays in diagnosis of psoriatic arthritis (PsA) are associated with indolent and non-specific signs and symptoms, and often result in physical impairment and poorer…
Abstract Number: 0674 • ACR Convergence 2024
Hydroxychloroquine Screening Adherence: Insights from Highmark Claims Data
Sara Shahid¹, Tyson Barrett², Sonia Manocha¹ and Tanmayee Bichile¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ)-associated retinal toxicity and vision loss are significant challenges, with a 2% prevalence in patients using HCQ for over 10 years and up…
Abstract Number: 1518 • ACR Convergence 2024
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Maria Cuellar-Gutierrez¹, Jaime Flores Gouyonnet¹, Gabriel Figueroa-Parra², Marta Casal Moura¹, Fernando C. Fervenza¹, Andrew C. Hanson³, Cynthia Crowson¹, Sanjeev Sethi¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Mayo Clinic, Rochester
Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
Abstract Number: 2340 • ACR Convergence 2024
Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
Jessica A Walsh¹, Shaobo Pei², Gopi Penmetsa³, Swetha Alexander⁴, Nga Lori Ly⁵, Rosario Adriana Molano-Romero⁴, April Conlon⁶, Catherine Bakewell⁷, Soumya Reddy⁸, Jose Scher⁹ and Alexis Ogdie¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²University of Utah, Thousand Oaks, CA, ³University Of Utah Hospital, Salt Lake City, UT, ⁴University of Utah Health, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Utah, Sandy, UT, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸NYU Grossman School of Medicine, New York, NY, ⁹New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diagnostic delays are common in psoriatic arthritis (PsA). Screening surveys administered in clinic can identify psoriasis patients at elevated risk for PsA who should…
Abstract Number: 0694 • ACR Convergence 2024
A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database
Stefano Di Donato¹, Michael Hughes², John Pauling³, Marco Matucci-Cerinic⁴, Lesley-Anne Bissell⁵, Edward Jude⁶, Christopher Denton⁷, Yannick Allanore⁸, Marie-Elise Truchetet⁹ and Francesco Del Galdo¹⁰, and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴University San Raffaele Milano, Milano, Milan, Italy, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸Université Paris Cité, Paris, France, ⁹Bordeaux University Hospital, Bordeaux, France, ¹⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Vascular dysfunction is pivotal in Systemic Sclerosis (SSc) pathogenesis, leading to somatic vascular signs such as pitting scars, Digital Ulcers (DUs), telangiectasia as well…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 2389 • ACR Convergence 2024
Choroidal Thickness in Active Lupus Nephritis
Leticia Maria Kolachinski R Brandao¹, Lucas Parente de Andrade², Débora Cordeiro do Rosário³, Paula Letícia De Queiroz e Barbosa⁴, Francisco Formiga³, Carolina Torres Ribeiro⁵, Tatiana do Nascimento Pedrosa³, Maria Fernanda Abalem de Sá Carricondo⁶, Pedro Carlos Carricondo², Eloisa Bonfa³ and Michelle Remiao Ugolini Lopes³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Campinas, SP, Brazil, ²Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, ⁵Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁶Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Lupus choroidopathy was reported to be a marker of severe systemic lupus erythematosus (SLE) activity, commonly associated with nephropathy. However, it remains controversial if…

« Previous Page
1
…
5
6
7
8
9
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].